FLNA

Filana Therapeutics, Inc. (FLNA) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Negative ROIC and absent margin disclosure indicate weak internal economics, but the negative cash conversion cycle supports working-capital efficiency versus more capital-intensive peers.

A current and quick ratio above 2.0 suggests liquidity resilience, which is stronger than many leveraged small-cap peers facing tighter near-term funding flexibility.

Net debt to EBITDA near 2.0 implies manageable leverage, leaving FLNA less financially constrained than higher-debt peers in the same coverage universe.

Weaknesses

Score:

ROIC is deeply negative, showing capital deployment is destroying value and leaving FLNA structurally weaker than profitable peers with positive spread economics.

Missing operating and gross margin disclosure limits transparency, but the available profitability signal remains poor relative to peers with durable margin buffers.

Leverage is not extreme, yet net debt to EBITDA near 2.0 still reduces strategic flexibility versus cleaner balance-sheet peers with lower refinancing risk.

Opportunities

Score:

If working-capital discipline persists, the negative cash conversion cycle can continue to support liquidity and free cash flow relative to peers with slower cash turns.

Balance-sheet capacity could be used to fund operational improvements, which would matter more for FLNA than for peers already operating near optimal leverage.

Improving capital efficiency would have outsized impact because the current negative ROIC leaves more room to close the gap versus stronger peers.

Threats

Score:

Persistently negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest more aggressively and compound market share over time.

If leverage rises or earnings weaken, net debt to EBITDA near 2.0 could become more constraining than for peers with stronger cash generation.

The absence of disclosed margin metrics increases uncertainty, and peers with clearer profitability profiles may attract capital and customer confidence more easily.

Overall Score

Score:

FLNA’s structural positioning appears weak versus peers because deeply negative ROIC outweighs acceptable liquidity and moderate leverage, leaving limited evidence of durable advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Filana Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →